cervical cancer news from FierceBiotech

> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of Read more...

Sysmex and Matritech have dissolved a 2002 agreement under which Sysmex was granted a license for the use of Matritech's NMP 179 cervical cancer technology. Matritech, which is focused on Read more...

> Wyeth and Progenics say that a three-month extended study of their constipation therapy produced positive data. Release

> GlaxoSmithKline says that the biggest study yet has produced impressive data on the effectiveness of Cervarix in preventing cervical cancer. It will need plenty of powerful data if it intends to grab market share from Gardasil.  …

Read more...

Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines

Read more...

> Chutes & Ladders: Emisphere Technologies has fired its chairman and CEO, Dr. Michael Goldberg, without citing a reason for his dismissal. Lewis Bender, senior vice president of business development, takes over in the interim. Report

> Crucell has inked a development deal with Novo Nordisk to develop new antibodies. …

Read more...

BusinessWeek profiles Margaret McGlynn (photo), president of Merck Vaccines for the past 14 months. During that time, Merck has launched four vaccines, including Gardasil as a protection against cervical cancer. These vaccines are at the center of Merck's plans to revive the company from its post-Vioxx debacle. Gardasil alone is expected to generate $2 billion to $4 billion in annual revenue.

- here's the …

Read more...

> President Bush has signed a new law that expands the powers of federal authorities targeting the activities of animal rights groups. Report

> GlaxoSmithKline has won EMEA approval to market Hycamtin, a combinatorial therapy for cervical cancer. Report

> Affymax has …

Read more...

> Shares of Emisphere Technologies took a nasty hit today after the company reported negative Phase II data from a diabetes study. Report

> Switzerland's NovImmune raised $46 million in its second round of financing. …

Read more...

Morphotek lands $40M VC round

Read more...

Germany's MTM Laboratories has raised €22 million in its third round of venture funding. The developer says that much of that money will go to the development and commercialization of its diagnostic and screening devices for cervical cancer. HBM BioVentures and HBM BioCapital led the round.

"MTM Laboratories is taking a unique marker approach to the screening and diagnosis of cervical cancer, the largest existing screening market in oncology," said Dr. Erich Platzer, founding …

Read more...